Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HPGDS | O60760 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11422025 | 0.86 | PIN1 (0.62) | NPY5RPIN1KDM4E | |
| SCHEMBL4770414 | 0.83 | NPY5R (0.49) | NPY5RHPGDMAPTPIN1ALDH1A1 | |
| SCHEMBL6889908 | 0.80 | NPY5R (0.55) | NPY5RHPGDHPGDSMAPTKDM4C | |
| SCHEMBL4070066 | 0.78 | KDM4E (0.69) | HPGDBTKMKNK1MKNK2KDM4E | |
| SCHEMBL3536070 | 0.76 | SCN2A (0.50) | PIN1 | |
| SCHEMBL24575111 | 0.75 | EGLN1 (0.67) | — | |
| SCHEMBL11236769 | 0.74 | KDM4E (0.50) | NPY5RHPGDMKNK1MKNK2KDM4E | |
| SCHEMBL11666314 | 0.74 | PIN1 (0.54) | NPY5RHPGDMAPTPIN1KDM4E | |
| SCHEMBL9205892 | 0.73 | GUSB (0.51) | — | |
| SCHEMBL1442878 | 0.73 | RECQL (0.73) | NPY5RHPGDHPGDSMAPTKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795271-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | PFIZER INC | 2009-12-10 | — | — | US | disclosed |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | PHARMACIA CORPORATION (US) | 2007-07-19 | — | — | US | disclosed |
| CN-1968937-A | Pyrimidin-4-one derivatives and their use as P38 kinase modulators | PHARMACIA CORP (US) | 2007-05-23 | — | — | CN | disclosed |
| US-7183287-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2007-02-27 | — | — | US | disclosed |
| EP-1753731-A2 | PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS P38 KINASE MODULATORS | Pharmacia Corporation (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20040242608-A1 | Substituted pyrimidinones | PHARMACIA LLC | 2004-12-02 | — | — | US | disclosed |
| WO-2004087677-A2 | PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS P38 KINASE MODULATORS | PHARMACIA CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | NPY5R 1762/4885HPGD 418/4885HPGDS 100/4885 |
| US-20040242608-A1 | Substituted pyrimidinones | MAPK1, MAPK7, MAP3K8 | NPY5R 1979/4885HPGD 442/4885HPGDS 69/4885 |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | NPY5R 1762/4885HPGD 418/4885HPGDS 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.